Graphy Inc. Establishes 'Smart Clinics for Clear Aligners' in Major Cities… Plans to Expand Nationwide
Three Partner Dental Clinics Selected in Seoul, Gwangju, and Busan
Establishing an SMA Treatment Network
Introduction of a Direct Supply System from Headquarters… Full-Scale Launch of B2C Marketing
[Edaily Reporter Hyera Lee ] #Graphy Inc. announced on the 10th that it has partnered with J-Vise Group, a consulting firm specializing in hospitals, to select three “SMA Reserve Smart Clinics” in Seoul, Gwangju, and Busan and is set to launch full-scale marketing campaigns targeting patients. Graphy Inc. CI. (Photo courtesy of Graphy Inc.) The selected medical institutions—one each in Seoul, Gwangju, and Busan—mark the beginning of Graphy Inc.’s plan to expand its partnership network to major regions nationwide, thereby increasing access to treatment with shape-memory alloy (SMA) clear aligners. The Reserve Smart Clinics operate on a direct supply system that provides shape-memory SMA produced directly by Graphy Inc.’s headquarters. This allows medical staff to use products of consistent quality, and patients to receive treatment under Graphy Inc.’s quality control system. This initiative marks the first instance of Graphy Inc. moving beyond its existing business-to-business (B2B) marketing focused on medical professionals to fully launch business-to-consumer (B2C) marketing. Graphy Inc. will handle product supply and clinical support, while working with specialized partners to attract patients and conduct marketing efforts in each region. Graphy Inc. plans to expand its network of partner clinics to major regions nationwide—including the Seoul Metropolitan Area, the Chungcheong, Yeongnam, and Honam regions—and increase the adoption of SMA. Graphy Inc. representative stated, “SMA-based clear aligner treatments will begin in earnest at each clinic starting at the end of this month,” adding, “Given the growing interest—as evidenced by the participation of over 700 dental professionals in a recent SMA online seminar—we will expand the adoption of SMA by conducting clinical training and patient marketing in tandem.”
Tension is mounting in the domestic credit market after the U.S. Federal Reserve (Fed) raised its benchmark interest rate last September for the first time in about three years. As inflationary pressu…
Voronoi, Inc.(310210)’s new anticancer drug candidate “VRN10” (VRN101099) demonstrated early antitumor activity by achieving a partial response (PR) in patients with HER2-mutated solid tumors. However…
Rainbow Robotics(277810)reported a widening net loss in the third quarter of this year despite revenue growth. While sales to its largest shareholder, SamsungElectronics, increased, the proportion of …